Andreas Engert
Led the GHSG for two decades, running the HD10 to HD18 trials that cure over 90% of Hodgkin lymphoma with less treatment.
Overview
Andreas Engert chaired the German Hodgkin Study Group from 2007 to 2020, leading HD10 (two cycles of ABVD plus 20 Gy for early favourable disease), HD15 (six cycles of escalated BEACOPP with PET-guided radiotherapy omission) and HD18, which together defined modern risk- and PET-adapted Hodgkin lymphoma therapy with cure rates above 90%. He was president of the European Hematology Association.
Pages like this
not linked directly; found by shared links- PersonPeter Borchmann
Shares German Hodgkin Study Group, Uniklinik Köln (CIO), FDG PET, Hodgkin lymphoma and the tags hodgkin, ghsg.
- PersonHisham Mehanna
Shares FDG PET and the tag de-escalation.
- ProductChlorambucil
Shares Hodgkin lymphoma, Cytotoxic chemotherapy.
- ProductDacarbazine
Shares Hodgkin lymphoma, Cytotoxic chemotherapy.
- TermLugano classification / Ann Arbor staging
Shares FDG PET, Hodgkin lymphoma.
- PersonAleix Prat
Shares FDG PET and the tag de-escalation.
- PersonMichael Hallek
- TermDeauville five-point scale
Shares FDG PET, Hodgkin lymphoma.